Fruquintinib
This oral medication inhibits VEGF receptors that promote tumor blood vessel formation, cutting off the blood supply that colorectal and lung tumors need to grow. It is used in later lines of treatment for metastatic colorectal cancer and non-small cell lung cancer that has progressed on prior therapies.
Masse moléculaire
393,4000 g/mol
LogP
3,40
TPSA
95,70 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Structure 2D
Cite this structure
Embed this structure
SMILES
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
InChI
InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)
Molecular Formula
C21H19N3O5
HBD / HBA
1 / 7
Liaisons Rotatives
5
Atomes Lourds
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
This oral medication inhibits VEGF receptors that promote tumor blood vessel formation, cutting off the blood supply that colorectal and lung tumors need to grow. It is used in later lines of treatment for metastatic colorectal cancer and non-small cell lung cancer that has progressed on prior therapies.
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Yes, Fruquintinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4303214. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44480399. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fruquintinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fruquintinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fruquintinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fruquintinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fruquintinib"></drugfyi-drug>